Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Two GSK3862995B Formulations in Healthy Participants
NCT07789899Phase 1Recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gsk3862995b in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoints: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration at Week 36, Maximum Observed Serum Concentration at Week 36 and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
gsk3862995b
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07789899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789899.